HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INNOGEN-B

20.900

+0.6002.96%

Volume:886.60K

Turnover:18.70M

Market Cap:9.55B

PE:-23.37

High:22.300

Open:20.300

Low:20.300

Close:20.300

52wk High:74.000

52wk Low:19.050

Shares:457.00M

HK Float Shares:420.29M

Volume Ratio:0.43

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.894

ROE:-36.91%

ROA:-17.30%

PB:8.01

PE(LYR):-23.37

PS:64.17

Loading ...

Overview Company News Filings

INNOGEN-B (02591) Plans to Implement H-Share Full Circulation Scheme

Guangzhou Innogen files with CSRC to convert domestic unlisted shares into H shares for Hong Kong listing

INNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results

Bulletin Express

INNOGEN-B (02591) Announces February 2026 Monthly Return with No Change in Share Capital

Bulletin Express

Guangzhou Innogen (2591) Announces Joint Company Secretary Changes and Waiver Approval

Bulletin Express

INNOGEN-B (02591) Appoints Yang Dongyan as Joint Company Secretary

Guangzhou Innogen Pharmaceutical Appoints Yang as Joint Company Secretary

BUZZ-Guangzhou Innogen jumps most in 10 weeks on Veterinary Drug Application

Guangzhou Innogen Pharmaceutical (2591) Announces Acceptance of Investigational New Veterinary Drug Application for Efsubaglutide Alfa

Bulletin Express

INNOGEN-B (02591) Announces Acceptance of New Veterinary Drug Clinical Trial Application for Esupaglutide α

BRIEF-Guangzhou Innogen Pharmaceutical Says Veterinary Drug Application Accepted By MARA

Guangzhou Innogen Pharmaceutical Gets Investigational New Veterinary Drug Application for Efsubaglutide Alfa Accepted in China

Guangzhou Innogen Pharmaceutical Group Co Ltd - Investigational New Veterinary Drug Application Accepted by Mara

THOMSON REUTERS

Guangzhou Innogen (02591) Announces Monthly Return for January 2026

Bulletin Express

From Sharp Post-Connect Decline to "Doji Star": Is INNOGEN-B (02591) Nearing a Turning Point After Low-Level Consolidation?

HK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines

HKEX Announcement Highlights | Guoxia Tech Plans Global Offering of 33.85M H Shares, Secures Cornerstone Investors Including Wui Kai Hong

Innogen Pharma Added to Stock Connect Programs

MT Newswires Live

INNOGEN-B (02591) Pulls Back Over 13% After 50% Rally in Two Weeks, Officially Added to Stock Connect Today

INNOGEN-B (02591) Core Product Included in China's National Reimbursement Drug List

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02591/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":20.9,"timestamp":1774598898874,"preClose":20.3,"halted":0,"volume":886600,"delay":0,"changeRate":0.029556650246305313,"floatShares":420285370,"shares":457000000,"eps":-0.8941885403203698,"marketStatus":"Not Yet Opened","change":0.6,"latestTime":"03-27 16:08:18","open":20.3,"high":22.3,"low":20.3,"amount":18697560,"amplitude":0.098522,"askPrice":20.98,"askSize":200,"bidPrice":20.9,"bidSize":9400,"shortable":0,"etf":0,"ttmEps":-0.9360682567657541,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":0,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":20.3,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"volumeRatio":0.42672185590245676,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-17.30%","roe":"-36.91%","lyrEps":-0.894189,"volumeRatio":0.42672185590245676,"shares":457000000,"dividePrice":0,"high":22.3,"amplitude":0.098522,"preClose":20.3,"low":20.3,"week52Low":19.05,"pbRate":"8.01","psRate":"64.17","week52High":74,"institutionHeld":0,"latestPrice":20.9,"committee":0.958333,"eps":-0.8941885403203698,"divideRate":0,"volume":886600,"delay":0,"ttmEps":-0.9360682567657541,"open":20.3,"prevYearClose":30.64,"prevWeekClose":21.6,"prevMonthClose":27.8,"prevQuarterClose":30.64,"fiveDayClose":21.6,"twentyDayClose":27.8,"sixtyDayClose":31.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1770998400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-03-27","current":-22.289484,"percent":0.993377,"low":-137.156472,"twenty":-78.775514,"median":-59.491697,"eighty":-50.290678,"high":-23.991974,"avg":-65.482151,"sd":21.166852,"marketCap":9547524394},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-20","current":-50.419859,"twenty":-79.623791,"median":-62.643943,"eighty":-56.891323,"marketCap":12653895967},{"date":"2026-02-27","current":-50.052949,"twenty":-79.470699,"median":-62.017016,"eighty":-56.651056,"marketCap":12699577902},{"date":"2026-03-06","current":-43.88908,"twenty":-79.397543,"median":-60.902753,"eighty":-56.29247,"marketCap":11045891858},{"date":"2026-03-13","current":-39.965904,"twenty":-79.214462,"median":-60.292057,"eighty":-54.71959,"marketCap":10104843999},{"date":"2026-03-20","current":-39.174717,"twenty":-78.964109,"median":-59.813644,"eighty":-50.865048,"marketCap":9867297938},{"date":"2026-03-27","current":-24.701097,"twenty":-78.775514,"median":-59.491697,"eighty":-50.290678,"marketCap":9547524394}],"updateTime":1774799163584},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1172970710","title":"INNOGEN-B (02591) Plans to Implement H-Share Full Circulation Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1172970710","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172970710?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:40","pubTimestamp":1773744032,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that on March 17, 2026, the company submitted an application to the China Securities Regulatory Commission for the proposed conversion of all its domestic unlisted shares...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2620547425","title":"Guangzhou Innogen files with CSRC to convert domestic unlisted shares into H shares for Hong Kong listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620547425","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620547425?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:37","pubTimestamp":1773743875,"startTime":"0","endTime":"0","summary":"Innogen said it has submitted a filing application for the proposed conversion of all its domestic unlisted shares into H shares. The company plans to apply for the listing of, and permission to deal in, the converted H shares on the Hong Kong Stock Exchange’s Main Board. Innogen said the filing procedures are not yet complete and the implementation plan has not been finalised. It added that no shareholders’ meeting is required to approve the conversion and listing under its articles of association.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL49NV01:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":0},{"id":"1103949350","title":"INNOGEN-B (02591) Sets 23 March 2026 Board Meeting to Approve FY 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1103949350","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103949350?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:44","pubTimestamp":1773132241,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) has scheduled a board meeting for Monday, 23 March 2026. According to the official announcement released in Shanghai on 10 March...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"1144978709","title":"INNOGEN-B (02591) Announces February 2026 Monthly Return with No Change in Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1144978709","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144978709?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:18","pubTimestamp":1772615937,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (INNOGEN-B, 02591) released its monthly return for the period ended 28 February 2026, confirming no change in its issued share capital composition....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"1193841516","title":"Guangzhou Innogen (2591) Announces Joint Company Secretary Changes and Waiver Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1193841516","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193841516?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:02","pubTimestamp":1770368521,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) announced that a joint company secretary, Ms. Jin Jin, resigned effective 6 February 2026 for personal development reasons. Ms. Jin...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"1160518198","title":"INNOGEN-B (02591) Appoints Yang Dongyan as Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=1160518198","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160518198?lang=en_us&edition=fundamental","pubTime":"2026-02-06 16:46","pubTimestamp":1770367584,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that Ms. Jin Jin has resigned as joint company secretary for personal development reasons, effective February 6, 2026. Ms. Yang Dongyan has been appointed as joint company...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2609563466","title":"Guangzhou Innogen Pharmaceutical Appoints Yang as Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2609563466","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609563466?lang=en_us&edition=fundamental","pubTime":"2026-02-06 16:40","pubTimestamp":1770367227,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co. Ltd. has announced that Ms. Jin Jin has resigned as joint company secretary, effective 6 February 2026, and Ms. Yang has been appointed as the new joint company secretary.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL2JrjYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2609349781","title":"BUZZ-Guangzhou Innogen jumps most in 10 weeks on Veterinary Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2609349781","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609349781?lang=en_us&edition=fundamental","pubTime":"2026-02-05 11:35","pubTimestamp":1770262519,"startTime":"0","endTime":"0","summary":"BUZZ-Guangzhou Innogen jumps most in 10 weeks on Veterinary Drug Application** Shares of Guangzhou Innogen Pharmaceutical Group 2591.HK jump 20.1% to HK$31, on track for the biggest one-day pct rise since November 24** Stock hits its highest level since January 30, on course to snap four consecutive sessions of decline; second-biggest pct gainer in the Hang Seng Composite Index on healthcare .HSCIH, which slips 1% ** China-based pharmaceutical products developer says Investigational New Veterinary Drug application for core product Efsubaglutide Alfa for treatment of companion animal diabetes has been accepted by China's Ministry of Agriculture and Rural Affairs ** Says Phase I clinical trials are expected to commence in the first quarter of 2026** YTD, stock down 4.8%, benchmark Hang Seng Index .HSI up 3.4%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL1N3Z104W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1143745026","title":"Guangzhou Innogen Pharmaceutical (2591) Announces Acceptance of Investigational New Veterinary Drug Application for Efsubaglutide Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1143745026","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143745026?lang=en_us&edition=fundamental","pubTime":"2026-02-04 23:04","pubTimestamp":1770217456,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Stock Code: 2591) disclosed that on 4 February 2026, the Ministry of Agriculture and Rural Affairs of the People’s Republic of China accepted its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"1132560248","title":"INNOGEN-B (02591) Announces Acceptance of New Veterinary Drug Clinical Trial Application for Esupaglutide α","url":"https://stock-news.laohu8.com/highlight/detail?id=1132560248","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132560248?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:25","pubTimestamp":1770215109,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) has issued an announcement disclosing that on February 4, 2026, the application for a new veterinary drug clinical trial for the company's core product, Esupaglutide α, intended for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2608360965","title":"BRIEF-Guangzhou Innogen Pharmaceutical Says Veterinary Drug Application Accepted By MARA","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360965","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608360965?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:19","pubTimestamp":1770214764,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Says Veterinary Drug Application Accepted By MARAFeb 4 (Reuters) - Guangzhou Innogen Pharmaceutical Group Co Ltd 2591.HK:INVESTIGATIONAL NEW VETERINARY DRUG APPLICATION ACCEPTED BY MARAFurther company coverage: 2591.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z00NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2608236060","title":"Guangzhou Innogen Pharmaceutical Gets Investigational New Veterinary Drug Application for Efsubaglutide Alfa Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2608236060","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608236060?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:17","pubTimestamp":1770214664,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Gets Investigational New Veterinary Drug Application for Efsubaglutide Alfa Accepted in China. Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced that the Ministry of Agriculture and Rural Affairs of the People's Republic of China has officially accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa, a core product intended for the treatment of companion animal diabetes. The company expects to commence Phase I clinical trials in the first quarter of 2026. The company indicated that this acceptance provides a basis for future clinical trials and registration applications related to the drug.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL3l8DdN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2608360674","title":"Guangzhou Innogen Pharmaceutical Group Co Ltd - Investigational New Veterinary Drug Application Accepted by Mara","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360674","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608360674?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:17","pubTimestamp":1770214637,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z00NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"1182093044","title":"Guangzhou Innogen (02591) Announces Monthly Return for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1182093044","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182093044?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:09","pubTimestamp":1770109767,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (stock code: 02591) released its monthly return for equity securities as of January 31, 2026. According to the announcement, the total authorized...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"gpt_icon":0},{"id":"1187454123","title":"From Sharp Post-Connect Decline to \"Doji Star\": Is INNOGEN-B (02591) Nearing a Turning Point After Low-Level Consolidation?","url":"https://stock-news.laohu8.com/highlight/detail?id=1187454123","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187454123?lang=en_us&edition=fundamental","pubTime":"2026-01-31 12:39","pubTimestamp":1769834355,"startTime":"0","endTime":"0","summary":"Throughout the eventful year of 2025, the fervent Hong Kong IPO market birthed numerous \"star IPO candidates,\" and among this constellation of stars, INNOGEN-B (02591) still managed to stand out with...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1125323298","title":"HK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines","url":"https://stock-news.laohu8.com/highlight/detail?id=1125323298","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125323298?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:06","pubTimestamp":1765940775,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) surged over 3% intraday, reaching a 3.43% gain at press time to HK$32, with a turnover of HK$20.74 million. The company announced via its official WeChat account that Esupaglutide α...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"gpt_icon":0},{"id":"1187723737","title":"HKEX Announcement Highlights | Guoxia Tech Plans Global Offering of 33.85M H Shares, Secures Cornerstone Investors Including Wui Kai Hong","url":"https://stock-news.laohu8.com/highlight/detail?id=1187723737","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187723737?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:08","pubTimestamp":1765206503,"startTime":"0","endTime":"0","summary":"Key Developments:   - **Guoxia Tech (02655)**: Opens IPO subscription from Dec 8–11, proposing a global offering of 33.85 million H shares with cornerstone investors like Wui Kai Hong.   - **CStone...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1149","SG9999001069.SGD","00956","02655","BK1148","LU0254981946.USD","BK1161","LU0214875030.USD","BK1523","SGXZ90724238.SGD","LU0449509016.USD","HK0000252160.HKD","SG9999006597.SGD","LU0449515922.USD","LU0823040885.USD","SG9999002950.SGD","LU0531970944.HKD","BK1166","00916","01618","BK1583","BK1594","BK1539","SG9999003461.SGD","LU0054450605.USD","BK1558","BK1503","BK1119","02591","06166","00489","HK0000252152.HKD","HK0000500386.USD","SG9999001051.SGD","BK1565","BK1154","BK1240","SG9999001093.SGD"],"gpt_icon":0},{"id":"2589386476","title":"Innogen Pharma Added to Stock Connect Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2589386476","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589386476?lang=en_us&edition=fundamental","pubTime":"2025-12-08 12:57","pubTimestamp":1765169861,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  said its H shares have been added to both the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective Monday, according to a same-day bourse filing.The inclusion will allow mainland investors to trade the company's H shares through the Shanghai and Shenzhen stock exchanges.The board said the move is expected to broaden the firm's investor base, boost liquidity, and strengthen its profile in the capital market.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"1123349506","title":"INNOGEN-B (02591) Pulls Back Over 13% After 50% Rally in Two Weeks, Officially Added to Stock Connect Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1123349506","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123349506?lang=en_us&edition=fundamental","pubTime":"2025-12-08 10:24","pubTimestamp":1765160654,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) retreated more than 13%, following a 50% surge over the past two weeks. At the time of writing, the stock fell 13.64% to HK$38, with a turnover of HK$30.31 million. The Shanghai and...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":1},{"id":"1111408676","title":"INNOGEN-B (02591) Core Product Included in China's National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1111408676","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111408676?lang=en_us&edition=fundamental","pubTime":"2025-12-07 19:22","pubTimestamp":1765106529,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced that its core product, Esupaglutide α, has been successfully included in the latest edition of China's National Reimbursement Drug List (2025 version) for the treatment of type 2 diabetes (T2D). The updated list will officially take effect on January 1, 2026.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":66,"code":"91000000","status":"200"}]}}